魚躍醫療(002223.SZ)業績快報:2020年度淨利潤升138.04%至17.91億元
格隆匯 1 月 28日丨魚躍醫療(002223.SZ)發佈2020年度業績快報,實現營業總收入67.34億元,同比增長45.26%;營業利潤20.68億元,同比增長143.27%,歸屬於上市公司股東的淨利潤17.91億元,同比增長138.04%;基本每股收益1.787元。
報吿期內,公司製氧機、電子血壓計、血糖儀及試紙等主要產品繼續保持良好增長,部分核心業務增幅較大,各產品銷售工作全面提升,其中海外銷售業績突出,業務規模成倍增長,除妥善完成了大量海外訂單的對接統籌工作外,亦建立、拓寬了海外銷售渠道,品牌影響力得到加深,為長期業務開展提供了可能。線上平台業績表現同樣亮眼,同比增速超過30%,線下平台持續推進終端精細化策略,克服疫情負面影響,增速穩定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.